X

Trial Profile

A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QEQ 278 (Primary)
Indications Carcinoma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

22 Jan 2025 Planned End Date changed from 24 Feb 2025 to 13 Jun 2025.
22 Jan 2025 Planned primary completion date changed from 17 Feb 2025 to 13 Jun 2025.
28 Nov 2024 Planned End Date changed from 29 Jan 2025 to 24 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com